Nantkwest (NK) Receiving Somewhat Favorable Press Coverage, Accern Reports

News stories about Nantkwest (NASDAQ:NK) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nantkwest earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.9220695043375 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Several research analysts have weighed in on NK shares. Zacks Investment Research raised Nantkwest from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research report on Tuesday, November 14th. BidaskClub cut Nantkwest from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. Finally, Raymond James Financial reissued a “hold” rating on shares of Nantkwest in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $5.25.

Shares of Nantkwest (NK) opened at $4.44 on Wednesday. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. Nantkwest has a one year low of $2.71 and a one year high of $8.45.

ILLEGAL ACTIVITY WARNING: “Nantkwest (NK) Receiving Somewhat Favorable Press Coverage, Accern Reports” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at

Nantkwest Company Profile

NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

Insider Buying and Selling by Quarter for Nantkwest (NASDAQ:NK)

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with's FREE daily email newsletter.

Leave a Reply